Novo’s threat to sue Hims over Wegovy pill faces legal hurdlenews2026-02-05T21:25:38+00:00February 5th, 2026|Endpoints News|
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trialnews2026-02-05T17:15:12+00:00February 5th, 2026|Endpoints News|
Telehealth provider Hims goes after Novo’s weight loss pill with compounded versionnews2026-02-05T14:58:43+00:00February 5th, 2026|Endpoints News|
AbbVie says immunology blockbusters will be ‘main drivers’ of growth post-Humira news2026-02-04T20:40:50+00:00February 4th, 2026|Endpoints News|
GSK’s new CEO eyes more dealmaking, intense pipeline inspectionnews2026-02-04T15:01:47+00:00February 4th, 2026|Endpoints News|
Novartis says generics to erode $4B from 2026 salesnews2026-02-04T12:44:26+00:00February 4th, 2026|Endpoints News|
Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novonews2026-02-04T12:10:24+00:00February 4th, 2026|Endpoints News|
Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cutsnews2026-02-04T10:55:33+00:00February 4th, 2026|Endpoints News|
FDA seeks withdrawal of Amgen’s Tavneos, but company says it won’t pull drugnews2026-02-04T00:48:19+00:00February 4th, 2026|Endpoints News|
